Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call Transcript

SA Transcripts 161.49K Followers Follow Ultragenyx Pharmaceutical Inc. ( RARE ) Q2 2026 Earnings Call August 4, 2026 5:00 PM EDT Company Participants Joshua Higa - Director of Investor Relations & Corporate Communications Emil Kakkis - Founder, President, CEO & Director Erik Harris - Executive VP & Chief Commercial Officer Howard Horn - Executive VP of Corporate Strategy & CFO Eric Crombez - Chief Medical Officer & Executive VP Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Yaron Werber - TD Cowen, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Maurice Raycroft - Jefferies LLC, Research Division Eliana Merle - Barclays Bank PLC, Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Allison Bratzel - Piper Sandler & Co., Research Division Maxwell Skor - Morgan Stanley, Research Division Tazeen Ahmad - BofA Securities, Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Lydia Erdman - Goldman Sachs Group, Inc., Research Division Shelby Hill - RBC Capital Markets, Research Division Wing Yip - Wedbush Securities Inc., Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Amit Dayal - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good afternoon and welcome to the Ultragenyx Second Quarter 2026 Financial Results Conference Call. [Operator Instructions] It is now my pleasure to turn the call over to Joshua Higa, Chief of Staff and Vice President of Investor Relations. Joshua Higa Director of Investor Relations & Corporate Communications Thank you. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Howard Horn, Chief Financial Officer; Erik Harris, Chief Commercial Officer; and Eric Crombez, Chief Medical Officer. I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks